Sentences with phrase «brain metastases in»

Novel strategies that are effective in treating brain metastases in patients with lung cancer are needed.

[32] In patients with brain metastases in the AZD3759 phase I clinical trial, 63 % (12 of 19 patients) achieved an intracranial response and 50 % (10 of 20 patients) had an extracranial response.

Research from McMaster University has identified new regulators of brain metastases in patients with lung cancer.

Not exact matches

«Brain metastases represent an unmet need in current cancer care.

This means that when we rely on analysis of a primary tumour we may miss mutations in the brain metastases that we could potentially target and treat effectively with drugs.»

«We found genetic alterations in brain metastases that could affect treatment decisions in more than half of the patients in our study,» Dr Brastianos will say.

The genetic changes in brain metastases are independent of any occurring at the same time in the primary tumour, and in metastases elsewhere in the body, the researchers said.

Many lung cancer trials have traditionally excluded patients with brain metastases at baseline, expecting that the presence of metastases would create negative results that could in turn create the appearance of drug failure.

Brain metastases are the most common brain tumour in adults and are a leading cause of death in cancer patiBrain metastases are the most common brain tumour in adults and are a leading cause of death in cancer patibrain tumour in adults and are a leading cause of death in cancer patients.

«If you look at a set of lung cancer patients, like we did in the paper, who develop brain metastases, they all have those two genes in their primary lung cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hospital.

«Brain metastases are a secondary brain tumour, which means they are caused by cancer cells that escape from primary tumours like lung, breast or melanoma, and travel to the brain,» said Mohini Singh, the study's primary author and a PhD candidate in biochemistry at the Michael G. DeGroote School of Medicine at McMaBrain metastases are a secondary brain tumour, which means they are caused by cancer cells that escape from primary tumours like lung, breast or melanoma, and travel to the brain,» said Mohini Singh, the study's primary author and a PhD candidate in biochemistry at the Michael G. DeGroote School of Medicine at McMabrain tumour, which means they are caused by cancer cells that escape from primary tumours like lung, breast or melanoma, and travel to the brain,» said Mohini Singh, the study's primary author and a PhD candidate in biochemistry at the Michael G. DeGroote School of Medicine at McMabrain,» said Mohini Singh, the study's primary author and a PhD candidate in biochemistry at the Michael G. DeGroote School of Medicine at McMaster.

«Rare mutation may extend survival in lung cancer patients with brain metastases.»

Since whole - brain radiation is associated with significant cognitive effects and the use of additional radiation therapy for progression is common in this population, the Yale researchers suspect that patients with the ALK mutation would benefit from radiation focused on individual metastases.

Thus, based on the robust findings from the current study and until proven otherwise, WBRT may still have an important role for treatment of patients who are not in this specific disease category (i.e., 1 - 3 brain metastases).

Whole brain radiotherapy (WBRT) significantly improves tumor control in the brain after SRS, yet because of its association with cognitive decline, its role in the treatment of patients with brain metastases remains controversial.

Paul D. Brown, M.D., of Mayo Clinic, Rochester, Minn., and colleagues conducted a study in which 213 patients with 1 to 3 brain metastases were randomly assigned to receive SRS alone (n = 111) or SRS plus WBRT (n = 102).

«In cancer, it's usually the metastases to the lung, liver or brain that kill the patient, but it's hard to get tissue safely from these areas,» said Rick Lanman, MD, Guardant Health's chief medical officer.

In the case of breast cancer driven by overexpression of the HER2 gene, up to 50 percent of patients treated with targeted therapies eventually develop brain metastases, which are inevitably fatal.

They and additional co-authors at the MGH Cancer Center, the University of North Carolina, Vanderbilt University and Novartis, identified HER3 — part of the same signaling pathway that includes HER2 — as a possible contributor to anti-HER2 / PI3K resistance in breast cancer brain metastases.

After confirming in mouse models that cells from HER2 - positive breast cancers became resistant to anti-HER2 treatment when implanted into the brain but not into other tissues, the investigators found that HER3 is overexpressed in brain metastases of HER2 - positive breast cancers from both mice and human patients.

In their search for novel, tumor - specific therapies that could target multiple brain metastases without damaging adjacent tissues, the research team first developed a mouse model that more closely mimics what is seen in patientIn their search for novel, tumor - specific therapies that could target multiple brain metastases without damaging adjacent tissues, the research team first developed a mouse model that more closely mimics what is seen in patientin patients.

«Stem - cell - based therapy promising for treatment of breast cancer metastases in the brain.»

«Stem cell - based therapy for targeting skin - to - brain cancer: Stem cells loaded with oncolytic viruses show promising results in preclinical models for targeting skin cancer metastases in the brain.»

Several tests in cultured cells indicated that ganciclovir would cause the death of HSV - TK - expressing stem cells, and testing in the mouse model confirmed that administration of the drug after successful treatment of brain metastases successfully eliminated therapeutic stem cells that also expressed HSV - TK.

Tagged therapeutic stem cells (green) are targeting breast cancer metastases (red) in the brain of a mouse model.

«Metastatic brain tumors — often from lung, breast or skin cancers — are the most commonly observed tumors within the brain and account for about 30 percent of advanced breast cancer metastases,» says Khalid Shah, MS, PhD, director of the Molecular Neurotherapy and Imaging Laboratory in the MGH Departments of Radiology and Neurology, who led the study.

Current treatments for both primary brain tumors and brain metastases (cancer that has spread to the brain from another place in the body) are low in number and short on effectiveness.

P - glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model.

Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.

[21] In the recently presented FLAURA study, in which osimertinib was used in untreated patients with advanced EGFR - mutant NSCLC, the HR for systemic disease control and CNS control similarly favored osimertinib over erlotinib or gefitinib, supporting the preclinical data that showed osimertinib's penetration across the BBB and providing support for using this agent in first - line management of EGFR - mutant patients with brain metastaseIn the recently presented FLAURA study, in which osimertinib was used in untreated patients with advanced EGFR - mutant NSCLC, the HR for systemic disease control and CNS control similarly favored osimertinib over erlotinib or gefitinib, supporting the preclinical data that showed osimertinib's penetration across the BBB and providing support for using this agent in first - line management of EGFR - mutant patients with brain metastasein which osimertinib was used in untreated patients with advanced EGFR - mutant NSCLC, the HR for systemic disease control and CNS control similarly favored osimertinib over erlotinib or gefitinib, supporting the preclinical data that showed osimertinib's penetration across the BBB and providing support for using this agent in first - line management of EGFR - mutant patients with brain metastasein untreated patients with advanced EGFR - mutant NSCLC, the HR for systemic disease control and CNS control similarly favored osimertinib over erlotinib or gefitinib, supporting the preclinical data that showed osimertinib's penetration across the BBB and providing support for using this agent in first - line management of EGFR - mutant patients with brain metastasein first - line management of EGFR - mutant patients with brain metastases.

Characterization of passive permeability at the blood — tumor barrier in five preclinical models of brain metastases of breast cancer.

[22] Formal data on other compounds in development, including ASP8273, PF - 7775, EGF816, and HM61713, in patients with brain metastases are still awaited.

[38] The median time to CNS progression was 7 months in patients with previously untreated brain metastases.

Subgroup analyses showed benefit with the combination in all groups, with the exception of those with brain metastases at baseline, though this included a total of only 12 patients.

Early results from an ongoing trial suggest that pembrolizumab has promising activity in untreated melanoma patients with brain metastases.

Faculty in the Brain and Spinal Tumor Program focus on clinical research and treatment of primary brain tumors, neoplastic meningitis, brain metastases, epidural cord compression, neurotoxicities, anticancer agents, and cancer pain manageBrain and Spinal Tumor Program focus on clinical research and treatment of primary brain tumors, neoplastic meningitis, brain metastases, epidural cord compression, neurotoxicities, anticancer agents, and cancer pain managebrain tumors, neoplastic meningitis, brain metastases, epidural cord compression, neurotoxicities, anticancer agents, and cancer pain managebrain metastases, epidural cord compression, neurotoxicities, anticancer agents, and cancer pain management.

Undergoing immunotherapy within a month of stereotactic radiosurgery resulted in an improved response to treatment for patients with melanoma brain metastases.

Dr. Anders, a native of Burlington, N.C., an assistant professor in the University of North Carolina at Chapel Hill School of Medicine and a member of the UNC Lineberger Comprehensive Cancer Center, was chosen for her work on the identification of the prognosis and treatment of breast cancer brain metastases.